AMENDMENTS TO THE CLAIMS

1. **(Currently amended)** An immunogenic ~~vaccine~~ composition ~~for vaccinating dogs~~ comprising an agent capable of raising an immune response against *Mycoplasma cynos* (*M. cynos*) in a dog, wherein said agent comprises inactivated or attenuated *M. cynos*~~, and wherein said immune response is protective against Canine Infectious Respiratory Disease (CIRD).~~

2.-7. **(Canceled)**

8. **(Currently amended)** A pharmaceutical composition comprising an immunogenic ~~vaccine~~ composition according to Claim 1 and a pharmaceutically acceptable carrier, diluent or adjuvant.

9. **(Currently amended)** The immunogenic ~~vaccine~~ composition according to Claim 1 further comprising any one or more of:

an agent capable of raising an immune response in a dog against canine respiratory coronavirus (CRCV);

an agent capable of raising an immune response in a dog against canine parainfluenzavirus (CPIV);

an agent capable of raising an immune response in a dog against canine adenovirus type 2 (CAV-2);

an agent capable of raising an immune response in a dog against canine herpesvirus (CHV); and

an agent capable of raising an immune response in a dog against *Bordetella bronchiseptica* (*B. bronchiseptica*).

10. **(Currently amended)** An immunogenic ~~vaccine~~ composition according to Claim 9 wherein the agent capable of raising an immune response in a dog against CRCV comprises inactivated or attenuated CRCV.

11. **(Currently amended)** An immunogenic ~~vaccine~~ composition according to Claim 9 wherein the agent capable of raising an immune response in a dog against CRCV comprises a Spike protein or a hemagglutinin-esterase (HE) protein of CRCV, or an immunogenic portion of the Spike or HE protein.

12. **(Currently amended)** An immunogenic ~~vaccine~~ composition according to Claim 9 wherein the agent capable of raising an immune response in a dog against CPIV comprises inactivated or attenuated CPIV.

13. **(Currently amended)** An immunogenic ~~vaccine~~ composition according to Claim 9 wherein the agent capable of raising an immune response in a dog against CAV-2 comprises inactivated or attenuated CAV-2.

14. **(Currently amended)** An immunogenic ~~vaccine~~ composition according to Claim 9 wherein the agent capable of raising an immune response in a dog against CHV comprises inactivated or attenuated CHV.

15. **(Currently amended)** An immunogenic ~~vaccine~~ composition according to Claim 9 wherein the agent capable of raising an immune response in a dog against *B. bronchiseptica* comprises inactivated or attenuated *B. bronchiseptica.*

16. **(Withdrawn)** A method of eliciting an immune response in ~~vaccinating~~ a dog ~~against canine infectious respiratory disease (CIRD)~~ comprising administering to the dog an immunogenic ~~vaccine~~ composition according to Claim 1.

17. **(Withdrawn)** A method of treating CIRD in a dog comprising administering to the dog an immunogenic ~~vaccine~~ composition according to Claim 1.

18. **(Withdrawn)** A method of stimulating an immune response against *M. cynos*, the method comprising administering to a ~~the~~ dog an immunogenic composition according to Claim 1, wherein said immunogenic composition stimulates an immune response ~~agent capable of raising an immune response~~ against *M. cynos* in the [[a]] dog.

19. **(Withdrawn)** The method according to Claim 18 further comprising administering to the dog any one or more of:

an agent capable of raising an immune response against *S. zooepidemicus* in a dog;

an agent capable of raising an immune response against a *Chlamydophila* in a dog

an agent capable of raising an immune response in a dog against CRCV;

an agent capable of raising an immune response in a dog against CPIV;

an agent capable of raising an immune response in a dog against CAV-2;

an agent capable of raising an immune response in a dog against CHV; and

an agent capable of raising an immune response in a dog against *B. bronchiseptica.*

20.-39. **(Canceled)**

40. **(Currently amended)** An immunogenic ~~vaccine~~ composition comprising:

(b) an agent capable of raising an immune response against *M. cynos* in a dog; and

(d) an agent capable of raising an immune response against CRCV in a dog.

41. **(Currently amended)** The immunogenic ~~vaccine~~ composition according to Claim 40 further comprising any one or more of:

(c) an agent capable of raising an immune response against a *Chlamydophila* in a dog;

(e) an agent capable of raising an immune response in a dog against CPIV;

(f) an agent capable of raising an immune response in a dog against CAV-2;

(g) an agent capable of raising an immune response against CHV in a dog; and

(h) an agent capable of raising an immune response in a dog against *B. bronchiseptica.*

42. **(Currently amended)** The immunogenic ~~vaccine~~ composition according to Claim 40 further comprising:

(a) an agent capable of raising an immune response against *S. zooepidemicus* in a dog.

43.-56. **(Canceled)**

57. (**Currently amended**) The immunogenic ~~vaccine~~ composition according to Claim 1 further comprising an agent capable of raising an immune response against *Streptococcus equi sub species zooepidemicus* (*S. zooepidemicus*) in a dog.

58. (**Currently amended**) The immunogenic ~~vaccine~~ composition according to Claim 57 wherein the agent capable of raising an immune response against *S. zooepidemicus* in a dog comprises inactivated or attenuated *S. zooepidemicus*, or a structural protein of *S. zooepidemicus* ~~or an immunogenic portion thereof, or a sequence variant of said structural protein or immunogenic portion thereof,~~ or a nucleic acid encoding said structural protein~~, portion or~~

~~sequence variant, wherein said sequence variant has at least 90% sequence identity to the polypeptide sequence of said structural protein or immunogenic portion thereof~~.

59. (**Currently amended**) The immunogenic ~~vaccine~~ composition according to Claim.1 further comprising an agent capable of raising an immune response against a *Chlamydophila* in a dog.

60. (**Currently amended**) The immunogenic ~~vaccine~~ composition according to Claim 59 wherein the agent capable of raising an immune response in a dog against *Chlamydophila* comprises inactivated or attenuated *Chlamydophila abortus*, or a structural protein of *Chlamydophila abortus* ~~or an immunogenic portion thereof, or a sequence variant of said structural protein or immunogenic portion thereof,~~ or a nucleic acid encoding said structural protein~~, portion or sequence variant, wherein said sequence variant has at least 90% sequence identity to the polypeptide sequence of said structural protein or immunogenic portion thereof~~.

61. (**Currently amended**) The immunogenic ~~vaccine~~ composition according to Claim 59 wherein the agent capable of raising an immune response in a dog against a *Chlamydophila* comprises inactivated or attenuated *Chlamydophila psittaci*, or a structural protein of *Chlamydophila psittaci* ~~or an immunogenic portion thereof, or a sequence variant of said structural protein or immunogenic portion thereof,~~ or a nucleic acid encoding said structural protein~~, portion or sequence variant, wherein said sequence variant has at least 90% sequence identity to the polypeptide sequence of said structural protein or immunogenic portion thereof~~.

62. (**Currently amended**) The immunogenic ~~vaccine~~ composition according to Claim 59 wherein the agent capable of raising an immune response in a dog against a *Chlamydophila* comprises inactivated or attenuated *Chlamydophila felis*, or a structural protein of *Chlamydophila felis* ~~or an immunogenic portion thereof, or a sequence variant of said structural protein or immunogenic portion thereof,~~ or a nucleic acid encoding said structural protein~~, portion or sequence variant, wherein said sequence variant has at least 90% sequence identity to the polypeptide sequence of said structural protein or immunogenic portion thereof~~.

63. (**Currently amended**) The immunogenic ~~vaccine~~ composition according to Claim 59 wherein the agent capable of raising an immune response in a dog against a *Chlamydophila* comprises inactivated or[[.]] attenuated *Chlamydia muridarum*, *Chlamydia pecorum*, *Chlamydia pneumoniae*, *Chlamydia suis* or *Chlamydia trachomatis*, or a structural protein of *Chlamydia*

muridarum, *Chlamydia pecorum*, *Chlamydia pneumoniae*, *Chlamydia suis* or *Chlamydia trachomatis*~~, or an immunogenic portion thereof, or a sequence variant of said structural protein or immunogenic portion thereof,~~ or a nucleic acid encoding said structural ~~immunogenic~~ protein~~, portion or sequence variant, wherein said sequence variant has at least 90% sequence identity to the polypeptide sequence of said structural protein or immunogenic portion thereof~~.